Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms

References

• Liu CB, Itoh T, Arai K, Watanabe S. Constitutive activation of JAK2 confers murine interleukin-3-independent survival and proliferation of BA/F3 cells. J. Biol. Chem.274(10), 6342–6349 (1999).
   PubMedGoogle Scholar
• Liu RY, Fan C, Garcia R, Jove R, Zuckerman KS. Constitutive activation of the JAK2/STAT5 signal transduction pathway correlates with growth factor independence of megakaryocytic leukemic cell lines. Blood93(7), 2369–2379 (1999).
   PubMed Web of Science ®Google Scholar
• Takemoto S, Mulloy JC, Cereseto A et al. Proliferation of adult T cell leukemia/lymphoma cells is associated with the constitutive activation of JAK/STAT proteins. Proc. Natl Acad. Sci. USA94(25), 13897–13902 (1997).
   PubMed Web of Science ®Google Scholar
• Baxter EJ, Scott LM, Campbell PJ et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet365(9464), 1054–1061 (2005).
   PubMed Web of Science ®Google Scholar
• James C, Ugo V, Le Couedic JP et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature434(7037), 1144–1148 (2005).
   PubMed Web of Science ®Google Scholar
• Kralovics R, Passamonti F, Buser AS et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med.352(17), 1779–1790 (2005).
   PubMed Web of Science ®Google Scholar
• Levine RL, Wadleigh M, Cools J et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell7(4), 387–397 (2005).
   PubMed Web of Science ®Google Scholar
• Zhao R, Xing S, Li Z et al. Identification of an acquired JAK2 mutation in polycythemia vera. J. Biol. Chem.280(24), 22788–22792 (2005).
   PubMed Web of Science ®Google Scholar
• Tefferi A. Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era. Hematology Am. Soc. Hematol. Educ. Program240–245 (2006).
   PubMedGoogle Scholar
• Passamonti F, Rumi E, Pungolino E et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am. J. Med.117(10), 755–761 (2004).
   PubMed Web of Science ®Google Scholar
• Mesa RA, Elliott MA, Schroeder G, Tefferi A. Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia. Mayo Clin. Proc.79(7), 883–889 (2004).
   PubMed Web of Science ®Google Scholar
• Thomas DA, Giles FJ, Albitar M et al. Thalidomide therapy for myelofibrosis with myeloid metaplasia. Cancer106(9), 1974–1984 (2006).
   PubMed Web of Science ®Google Scholar
• Tefferi A, Cortes J, Verstovsek S et al. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood108(4), 1158–1164 (2006).
   PubMed Web of Science ®Google Scholar
• Deeg HJ, Gooley TA, Flowers MED et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood102(12), 3912–3918 (2003).
   PubMed Web of Science ®Google Scholar
• Cervantes F, Dupriez B, Pereira A et al. A new prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood113(13), 2895–2901 (2008).
   PubMed Web of Science ®Google Scholar
• Yamaoka K, Saharinen P, Pesu M, Holt VE 3rd, Silvennoinen O, O’Shea JJ. The Janus kinases (Jaks). Genome Biol.5(12), 253 (2004).
   PubMed Web of Science ®Google Scholar
• Bittorf T, Jaster R, Ludtke B, Kamper B, Brock J. Requirement for JAK2 in erythropoietin-induced signalling pathways. Cell Signal.9(1), 85–89 (1997).
   PubMedGoogle Scholar
• Sattler M, Durstin MA, Frank DA et al. The thrombopoietin receptor c-MPL activates JAK2 and TYK2 tyrosine kinases. Exp. Hematol.23(9), 1040–1048 (1995).
   PubMed Web of Science ®Google Scholar
• Brizzi MF, Aronica MG, Rosso A, Bagnara GP, Yarden Y, Pegoraro L. Granulocyte–macrophage colony-stimulating factor stimulates JAK2 signaling pathway and rapidly activates p93fes, STAT1 p91, and STAT3 p92 in polymorphonuclear leukocytes. J. Biol. Chem.271(7), 3562–3567 (1996).
   PubMed Web of Science ®Google Scholar
• Neubauer H, Cumano A, Muller M, Wu H, Huffstadt U, Pfeffer K. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell93(3), 397–409 (1998).
   PubMed Web of Science ®Google Scholar
• Parganas E, Wang D, Stravopodis D et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell93(3), 385–395 (1998).
   PubMed Web of Science ®Google Scholar
• Harpur AG, Andres AC, Ziemiecki A, Aston RR, Wilks AF. JAK2, a third member of the JAK family of protein tyrosine kinases. Oncogene7(7), 1347–1353 (1992).
   PubMed Web of Science ®Google Scholar
• Saharinen P, Silvennoinen O. The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J. Biol. Chem.277(49), 47954–47963 (2002).
   PubMed Web of Science ®Google Scholar
• Wernig G, Kharas MG, Okabe R et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell13(4), 311–320 (2008).
   PubMed Web of Science ®Google Scholar
• Pardanani AD, Gotlib J, Jamieson C et al. A Phase I study of TG101348, an orally bioavailable JAK2-selective inhibitor, in patients with myelofibrosis. ASH Annual Meeting Abstracts112(11) (2008) (Abstract 97).
   Google Scholar
• Verstovsek S, Kantarjian HM, Pardanani AD et al. The JAK inhibitor, INCB018424, demonstrates durable and marked clinical responses in primary myelofibrosis (PMF) and post-polycythemia/essential thrombocythemia myelofibrosis (Post PV/ETMF). ASH Annual Meeting Abstracts112(11) (2008) (Abstract 1762).
   Google Scholar
• Mesa RA, Schwager S, Radia D et al. Assessment and monitoring of constitutional symptoms in patients with myelofibrosis: a proposed new instrument the myelofibrosis symptom assessment form (MFSAF). ASH Annual Meeting Abstracts112(11) (2008) (Abstract 1754).
   Google Scholar
• Tefferi A, Kantarjian HM, Pardanani AD et al. The clinical phenotype of myelofibrosis encompasses a chronic inflammatory state that is favorably altered by INCB018424, a selective inhibitor of JAK1/2. ASH Annual Meeting Abstracts112(11) (2008) (Abstract 2804).
   Google Scholar
• Verstovsek S, Kantarjian HM, Pardanani AD et al. Characterization of JAK2 V617F allele burden in advanced myelofibrosis (MF) patients: no change in V617F:WT JAK2 ratio in patients with high allele burdens despite profound clinical improvement following treatment with the JAK inhibitor, INCB018424. ASH Annual Meeting Abstracts112(11) (2008) (Abstract 2802).
   Google Scholar
• Paquette R, Sokol L, Shah NP et al. A Phase I study of XL019, a selective JAK2 inhibitor, in patients with polycythemia vera. ASH Annual Meeting Abstracts112(11) (2008) (Abstract 2810).
   Google Scholar
• Shah NP, Olszynski P, Sokol L et al. A Phase I study of XL019, a selective JAK2 inhibitor, in patients with primary myelofibrosis, post-polycythemia vera, or post-essential thrombocythemia myelofibrosis. ASH Annual Meeting Abstracts112(11) (2008) (Abstract 98).
   Google Scholar
• Guerini V, Barbui V, Spinelli O et al. Selective targeting of the JAK2V617F mutation in polycythemia vera and essential thrombocythemia by ITF2357, a novel histone deacetylase inhibitor. ASH Annual Meeting Abstracts,110(11) (2007) (Abstract 555).
   Google Scholar
• Rambaldi A, Dellacasa CM, Salmoiraghi S et al. A Phase 2A study of the histone-deacetylase inhibitor ITF2357 in patients with Jak2V617F positive chronic myeloproliferative neoplasms. ASH Annual Meeting Abstracts112(11) (2008)(Abstract 100).
   Google Scholar
• Giles F, Bergstrom DA, Garcia-Manero G et al. MK-0457 is a novel aurora kinase and janus kinase 2 (JAK2) inhibitor with activity in transformed JAK2-positive myeloproliferative disease (MPD). ASH Annual Meeting Abstracts108(11) (2006) (Abstract 4893).
   Google Scholar
• Levis M, Smith BD, Beran M et al. A randomized, open-label study of lestaurtinib (CEP-701), an oral FLT3 inhibitor, administered in sequence with chemotherapy in patients with relapsed AML harboring FLT3 activating mutations: clinical response correlates with successful FLT3 inhibition. ASH Annual Meeting Abstracts106(11) (2005) (Abstract 403).
   Google Scholar
• Dobrzanski P, Hexner E, Serdikoff C et al. CEP-701 is a JAK2 inhibitor which attenuates jak2/stat5 signaling pathway and the proliferation of primary cells from patients with myeloproliferative disorders. ASH Annual Meeting Abstracts108(11) (2006) (Abstract 3594).
   Google Scholar
• Moliterno AR, Roboz GJ, Carroll M, Luger S, Hexner E, Bensen-Kennedy DM. An open-label study of cep-701 in patients with JAK2 V617F-positive polycythemia vera and essential thrombocytosis. ASH Annual Meeting Abstracts112(11) (2008) (Abstract 99).
   Google Scholar
• Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized Phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J. Clin. Oncol.21(12), 2237–2246 (2003).
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med.350(21), 2129–2139 (2004).
   PubMed Web of Science ®Google Scholar
• Li Z, Xu M, Xing S et al. Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth. J. Biol. Chem.282(6), 3428–3432 (2007).
   PubMed Web of Science ®Google Scholar
• Albrightson-Winslow CR, Brickson B, King A et al. Beneficial effects of long-term treatment with SK&F 105685 in murine lupus nephritis. J. Pharmacol. Exp. Ther.255(1), 382–387 (1990).
   PubMedGoogle Scholar
• Amit-Vazina M, Shishodia S, Harris D et al. Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells. Br. J. Cancer93(1), 70–80 (2005).
   PubMed Web of Science ®Google Scholar
• Faderl S, Ferrajoli A, Harris D, Van Q, Kantarjian HM, Estrov Z. Atiprimod blocks phosphorylation of JAK–STAT and inhibits proliferation of acute myeloid leukemia (AML) cells. Leuk. Res.31(1), 91–95 (2007).
   PubMedGoogle Scholar
• Duan Z, Bradner J, Greenberg E et al. 8-benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic acid (SD-1008), a novel janus kinase 2 inhibitor, increases chemotherapy sensitivity in human ovarian cancer cells. Mol. Pharmacol.72(5), 1137–1145 (2007).
   PubMedGoogle Scholar
• Lucet IS, Fantino E, Styles M et al. The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. Blood107(1), 176–183 (2006).
   PubMed Web of Science ®Google Scholar
• Thompson JE, Cubbon RM, Cummings RT et al. Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor. Bioorg. Med. Chem. Lett.12(8), 1219–1223 (2002).
   PubMed Web of Science ®Google Scholar
• Sayyah J, Magis A, Ostrov DA, Allan RW, Braylan RC, Sayeski PP. Z3, a novel Jak2 tyrosine kinase small-molecule inhibitor that suppresses Jak2-mediated pathologic cell growth. Mol. Cancer Ther.7(8), 2308–2318 (2008).
   PubMedGoogle Scholar
• Grandage VL, Everington T, Linch DC, Khwaja A. Go6976 is a potent inhibitor of the JAK 2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cells. Br. J. Haematol.135(3), 303–316 (2006).
   PubMed Web of Science ®Google Scholar
• Muto A, Hori M, Sasaki Y et al. Emodin has a cytotoxic activity against human multiple myeloma as a Janus-activated kinase 2 inhibitor. Mol. Cancer Ther.6(3), 987–994 (2007).
   PubMed Web of Science ®Google Scholar
• Meydan N, Grunberger T, Dadi H et al. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature379(6566), 645–648 (1996).
   PubMed Web of Science ®Google Scholar
• Duek A, Lichman I, Shtalrid M, Berrebi A. The Jak2-inhibitor AG409 affects survival of BFU-E and CFU-GM of myeloproliferative disorder cells carrying the JAK2 V617F mutation. ASH Annual Meeting Abstracts,108(11) (2006) (Abstract 4907).
   Google Scholar
• Kapuria V, Bartholomeusz G, Kong L-Y et al. A novel small-molecule approach to inhibit Jak2 tyrosine kinase signaling. ASH Annual Meeting Abstracts110(11) (2007) (Abstract 1556).
   Google Scholar
• Manshouri T, Estrov Z, Quintas-Cardama A et al. WP1066 inhibits growth of human cells carrying the JAK2 V617F mutation. ASH Annual Meeting Abstracts108(11) (2006) (Abstract 4885).
   Google Scholar
• Ferrajoli A, Faderl S, Wang T et al. WP1066: a novel PI-3K inhibitor with antileukemic activity in philadelphia chromosome-positive ALL. ASH Annual Meeting Abstracts106(11) (2005) (Abstract 850).
   Google Scholar
• Mesa RA, Powell H, Lasho T, Dewald G, McClure R, Tefferi A. JAK2(V617F) and leukemic transformation in myelofibrosis with myeloid metaplasia. Leuk. Res.30(11), 1457–1460 (2006).
   PubMed Web of Science ®Google Scholar
• Theocharides A, Boissinot M, Girodon F et al. Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood110(1), 375–379 (2007).
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia22(7), 1299–1307 (2008).
   PubMed Web of Science ®Google Scholar
• Epling-Burnette PK, Liu JH, Catlett-Falcone R et al. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J. Clin. Invest.107(3), 351–362 (2001).
   PubMed Web of Science ®Google Scholar
• Dohner K, Du J, Corbacioglu A, Scholl C, Schlenk RF, Dohner H. JAK2V617F mutations as cooperative genetic lesions in t(8;21)-positive acute myeloid leukemia. Haematologica91(11), 1569–1570 (2006).
   PubMedGoogle Scholar
• Lo M-C, Peterson LF, Yan M et al. Identification of the JAK/STAT signaling pathway as a valid therapeutic target of t(8;21) acute myeloid leukemia using combined gene expression and promoter occupancy profiling. ASH Annual Meeting Abstracts112(11) (2008) (Abstract 3336).
   Google Scholar
• Schnittger S, Bacher U, Kern W, Haferlach C, Haferlach T. JAK2 seems to be a typical cooperating mutation in therapy-related t(8;21)/ AML1-ETO-positive AML. Leukemia21(1), 183–184 (2007).
   PubMed Web of Science ®Google Scholar
• Samanta AK, Lin H, Sun T, Kantarjian H, Arlinghaus RB. Jak2: a potential therapeutic target for chronic myelogenous leukemia (CML). ASH Annual Meeting Abstracts108(11) (2006) (Abstract 2121).
   Google Scholar
• Sun X, Layton JE, Elefanty A, Lieschke GJ. Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL – expressing cells, demonstrating synergy between AG490 and STI571. Blood97(7), 2008–2015 (2001).
   PubMed Web of Science ®Google Scholar
• Fridman J, Nussenzveig R, Liu P et al. Discovery and preclinical characterization of INCB018424, a selective JAK2 inhibitor for the treatment of myeloproliferative disorders. ASH Annual Meeting Abstracts110(11) (2007) (Abstract 3538).
   Google Scholar